Mei Sheng Duh
Managing Principal and Chief Epidemiologist, Analysis Group, Inc.
Dr. Mei Sheng Duh, a Managing Principal and the Chief Epidemiologist at Analysis Group, specializes in real-world evidence generation for product registration, post-approval safety studies, and health economics and outcomes research of pharmaceuticals, vaccines, and regenerative biotherapeutics. Dr. Duh has led multiple projects for new molecular entity approvals and product label expansion applications to the FDA and EMA, as well as HTA research for submissions to national payors, such as CMS in the US and the UK’s NICE. Her extensive research has appeared in over 280 peer-reviewed publications. Dr. Duh is also an adjunct in the biostatistics department at the Harvard T.H. Chan School of Public Health. She served as a chairperson of Drug Safety and Epidemiology for the Drug Information Association and was an adjunct assistant professor of Pharmacoeconomics and Pharmacoepidemiology at Massachusetts College of Pharmacy and Allied Health Sciences. She was appointed to an expert panel convened by the Foundation for the NIH's Observational Medical Outcomes Partnership (OMOP). Dr. Duh holds a Doctor of Science degree in pharmacoepidemiology from the Harvard School of Public Health, a Master of Public Health degree in chronic disease epidemiology from Yale Medical School, and a B.S. in pharmacy from Taiwan.
